Table 1.
Patients’ characteristics.
| Age (median) | 38–82 (61) |
| Gender, n (%) | |
| Male | 24 (60.0) |
| Female | 16 (40.0) |
| Pathology, n (%) | |
| Adenocarcinoma | 33 (82.5) |
| Squamous cell carcinoma | 5 (12.5) |
| Large cell carcinoma | 1 (2.5) |
| Pleomorphic carcinoma | 1 (2.5) |
| Performance status, n (%) | |
| 0 | 26 (65.0) |
| 1 | 9 (22.5) |
| 2 | 5 (12.5) |
| Cancer status, n (%) | |
| Advanced | 28 (70.0) |
| Recurrent | 12 (40.0) |
| Previous therapy, n | |
| Advanced (n = 28) | |
| 1st/2nd/3rd/4th lines | 2/9/8/9 |
| EGFR-TKI | 15 |
| Radiation | 5 |
| Recurrent (n = 12) | |
| EGFR-TKI | 5 |
| Radiation | 5 |
| Number of vaccinations (median) | 1–42 (6) |
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.